Wed, Sep 24, 2014, 12:26 AM EDT - U.S. Markets open in 9 hrs 4 mins

Recent

% | $
Quotes you view appear here for quick access.

CytRx Corporation Message Board

  • avr.imoraxlies avr.imoraxlies Mar 8, 2014 9:05 PM Flag

    Important Safety Information

    Serious and possibly permanent heart-related side effects that may lead to congestive heart failure can occur in patients treated with DOXIL®. Inform your doctor of any history of heart disease, radiation to your chest, or prior anticancer therapy. Your doctor will monitor your heart function.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • doxil will be replaced by aldoxorubicin in EVERY CANCER CATEGORY

    • Part 2
      There are many subtypes of Sarcoma and they were balanced in this trial. 30% US 20 Aus and India and 50% Europe. OS data sometime in 2014. CT scans collected every six weeks. Primary Enpoint: PFS 8.4 vs 4.7 months Pvalue .0002. Central Radiology Review: Aldo arm PFS 5.7 vs Doxo 2.8 months Pvale.018 improvement 2.9 months or 104%. PFS at 6 Months: 86% improvement in Aldo arm. 47% had not progressed in Aldoxo vs 24%. 95% improvement here. Overall Response Results: Complete Response: 2.7% for Aldox vs 0% for Doxo. Partial Response: 22.7% in Aldox vs 5.4% in Doxo Overall Response rate of 25.4 vs 5.4 in Doxo for invesigators in the scans read by investigators and site radiologists. The Central Lab Review was quite in line with the others: 0% Response in Doxo arm vs 23% partial and overall response in Aldox arm. Summary: In each endpoint there was quite the astonishing improvement Aldoxorubicin patients vs Doxorubicin patients. **One of the MAJOR BENEFITS of Aldoxorubicin vs Doxorubicin is that there was no clinical Cardiac Toxicity! No such effect with Aldox vs Dox with 18 cycles administered. They feel that they can continue to Administer Aldox until further progression as with Doxorubicin you have to stop due to Toxicity effects.

    • Doxil is the most toxic chemo drug on the market, and their number 1 concern - cardiac tissue damage is the main reason the FDA keeps giving aldoxorubicin the thumbs up, GREEN light GO, ORPHAN DRUG STATUS, Special Protocol Assessment and it will be used in conjunction with other drugs, but also as a first line, second line etc, pharmaceutical. 50 Sarcomas, 1 aldoxorubicin, the potential is incredible, CytRx has worldwide rights.

      Sentiment: Strong Buy

    • bump...

      Sentiment: Strong Buy

    • this is the most important post you will ever see on this board. Aldoxorubicin will replace doxil. If you want to win at the message board game, keep bumping up this post. This is the money maker. The game changer. The winner. Aldoxorubicin wins big time over doxil. The FDA will approve CytRx's submission and the stakes are heating up. Only a matter of time. Unless, they get bought out. The stakes are that big.

      Sentiment: Strong Buy

 
CYTR
2.71-0.04(-1.45%)Sep 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.